

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb

RRID:AB_2315049

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4060, RRID:AB_2315049

Antibody Information

URL: http://antibodyregistry.org/AB_2315049

Proper Citation: Cell Signaling Technology Cat# 4060, RRID:AB_2315049

Target Antigen: Phospho-Akt (Ser473)

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F.

Info: Rated by ISCC, Intestinal Stem Cell Consortium (check ras <https://iscc.coh.org/>).

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Consolidation on 7/2016: AB_916027, AB_2341228, AB_10234665, AB_916024

Antibody Name: Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb

Description: This recombinant monoclonal targets Phospho-Akt (Ser473)

Target Organism: monkey, rat, hamster, mouse, bovine, zebrafish, human

Clone ID: Clone D9E

Defining Citation: [PMID:23749404](#), [PMID:23825125](#)

Antibody ID: AB_2315049

Vendor: Cell Signaling Technology

Catalog Number: 4060

Alternative Catalog Numbers: 4060L, 4060T, 4060S

Record Creation Time: 20250819T222131+0000

Record Last Update: 20250820T015621+0000

Ratings and Alerts

- Rated by ISCC, Intestinal Stem Cell Consortium - ISCC
<https://isccconsortium.org/resourcecatalog/>

No alerts have been found for Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1295 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xiong H, et al. (2026) MicroRNA-200s attenuate demyelination caused by *Angiostrongylus cantonensis* in a mouse model by targeting phosphatase and tensin homolog. *Neural regeneration research*, 21(6), 2599.

Jing J, et al. (2026) Recombinant tissue plasminogen activator protects neurons after intracerebral hemorrhage through activating the PI3K/AKT/mTOR pathway. *Neural regeneration research*, 21(4), 1574.

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. *Oncogene*, 45(4), 577.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. *Cancer research*, 86(6), 1467.

Wetterwald L, et al. (2026) MYCT1-IFITM2/3 interaction links endothelial endolysosomal trafficking to white adipose tissue expansion. *The Journal of experimental medicine*, 223(5).

Chen J, et al. (2026) Upregulation of CENPM facilitates glioma progression via PI3K/AKT signaling pathway. *Genomics*, 118(1), 111163.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.

Zhang Y, et al. (2026) Yinhuo Decoction attenuates depression-like behaviors and promotes M2 microglia polarization by regulating PI3K/Akt/NF- κ B signaling pathway in a murine model of menopausal depression. *Journal of ethnopharmacology*, 363, 121365.

Meng F, et al. (2026) The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. *Nature communications*, 17(1), 614.

Xie C, et al. (2026) Lysosome-localized IRTKS condensates promote mTORC1 activity leading to MASLD and HCC. *Cell reports*, 45(2), 116893.

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. *Cell reports. Medicine*, 7(2), 102578.

Gonzalez Ramirez ML, et al. (2026) Signaling bias of the protease-activated receptor-1 is dictated by distinct GRK5 and β -arrestin-2 determinants. *Cell reports*, 45(3), 117041.

Shen Y, et al. (2026) CCL1-AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages. *Cancer immunology research*, 14(4), 676.

Wu X, et al. (2026) Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies. *British journal of pharmacology*.

Song J, et al. (2026) Ets1-dependent Mek-Erk signaling drives adipose tissue macrophage anti-inflammatory polarization to ameliorates insulin resistance. *Cell reports*, 45(4), 117244.

Luque M, et al. (2026) Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. *Neoplasia (New York, N.Y.)*, 78, 101318.

Goldman A, et al. (2026) An LRRK2 variant blocks NCOA4 trafficking upon iron overload, leading to ferroptotic death. *Journal of cell science*, 139(14).

Ge X, et al. (2026) PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. *Cancer research*, 86(15), 3819.

Luo S, et al. (2026) Pan-cancer neurotransmitter receptor alterations define neuroregulatory subtypes with prognostic significance. *Cell reports*, 45(5), 117340.

Chien JY, et al. (2026) Nostoc commune Extract Attenuates Oxidative Stress and Neuroinflammation in Ischemic Optic Neuropathy Through PI3K/AKT/mTOR Signaling. *Antioxidants (Basel, Switzerland)*, 15(5).